ES2157326T3 - Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea. - Google Patents

Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea.

Info

Publication number
ES2157326T3
ES2157326T3 ES95916845T ES95916845T ES2157326T3 ES 2157326 T3 ES2157326 T3 ES 2157326T3 ES 95916845 T ES95916845 T ES 95916845T ES 95916845 T ES95916845 T ES 95916845T ES 2157326 T3 ES2157326 T3 ES 2157326T3
Authority
ES
Spain
Prior art keywords
apc
pct
factor
cleavage sites
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95916845T
Other languages
English (en)
Inventor
Johannes Jacobus Voorberg
Mourik Jan Aart Van
Koenraad Mertens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Application granted granted Critical
Publication of ES2157326T3 publication Critical patent/ES2157326T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)

Abstract

ESTA INVENCION SE REFIERE AL DIAGNOSTICO DEL DEFECTO CONGENITO EN EL SISTEMA ANTICOAGULANTE DE LA PROTEINA C. LOS METODOS DESCRITOS ESTAN BASADOS EN LA DETECCION DE MUTACIONES EN LOS SITIOS DE DIVISION DE LOS FACTORES DE COAGULACION QUE ESTAN BAJO CONTROL DE LA PROTEINA C ACTIVADA (APC). PRUEBAS DE DIAGNOSTICO INCLUYEN ANALISIS DE LOS SITIOS DE DIVISION APC DE FACTOR V Y FACTOR VIII, MEDIANTE EL USO DE INICIADORES ESPECIFICOS PARA AMPLIFICAR SELECTIVAMENTE A PARTIR DE ARN, ADNC DERIVADO DE ARN O ADN CROMOSOMAL, PARTES DEL FACTOR V Y FACTOR VIII QUE CONTIENEN SITIOS DE DIVISION PARA APC. SE DESCRIBEN METODOS QUE CONTROLAN LA PRESENCIA DE MUTACIONES EN EL SITIO DE DIVISION DEL APC Y SU UTILIDAD EN EL DIAGNOSTICO DE TRASTORNOS TROMBO-EMBOLICOS.LA INVENCION ADEMAS DESCRIBE METODOS PARA CORREGIR LOS DEFECTOS DETECTADOS DE ACUERDO A LA INVENCION, ASI COMO NUEVOS AGENTES TERAPEUTICOS QUE PUEDEN SER USADOS EN EL TRATAMIENTO DE TRASTORNOS HEMORRAGICOS, DICHOS AGENTES ESTAN BASADOS EN LAS PROTEINAS DE FACTOR V Y FACTOR VIII DEFECTUOSAS QUE PRODUCEN LOS TRASTORNOS TROMBOTICOS DESCRITOS ARRIBA.
ES95916845T 1994-04-22 1995-04-21 Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea. Expired - Lifetime ES2157326T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94201116 1994-04-22

Publications (1)

Publication Number Publication Date
ES2157326T3 true ES2157326T3 (es) 2001-08-16

Family

ID=8216820

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95916845T Expired - Lifetime ES2157326T3 (es) 1994-04-22 1995-04-21 Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea.

Country Status (11)

Country Link
US (1) US6083905A (es)
EP (1) EP0756638B1 (es)
JP (1) JP3810080B2 (es)
AT (1) ATE200225T1 (es)
AU (1) AU697205B2 (es)
CA (1) CA2188463C (es)
DE (1) DE69520569T2 (es)
DK (1) DK0756638T3 (es)
ES (1) ES2157326T3 (es)
GR (1) GR3036000T3 (es)
WO (1) WO1995029259A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT807691E (pt) 1994-02-14 2002-04-29 Univ Leiden Metodo para a pesquisa quanto a presenca de um defeito genetico associado a trombose e/ou fraca resposta anticoagulante a proteina c activada
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US6531455B1 (en) * 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5874256A (en) * 1995-06-06 1999-02-23 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
GB9604267D0 (en) * 1996-02-29 1996-05-01 Royal Infirmary Of Edinburgh N Mutation assay
ATE203567T1 (de) 1998-03-19 2001-08-15 Instrumentation Lab Spa Verbesserte in vitro verfahren, testkits und reagenzien zum screening von blutgerinnungsfehlern
DE19858278A1 (de) * 1998-12-17 2000-06-21 Dade Behring Marburg Gmbh Verfahren zum Lokalisieren von Defekten im Gerinnungssystem
JP4676585B2 (ja) * 1999-12-24 2011-04-27 一般財団法人化学及血清療法研究所 血液凝固異常に基づく疾患の治療・予防用医薬組成物
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US7615622B2 (en) * 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
JP2005511599A (ja) * 2001-11-09 2005-04-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド及びｖ因子ポリペプチドを含む薬学的組成物
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
US7067541B2 (en) 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2006027111A1 (en) * 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
CN102793972A (zh) 2004-12-27 2012-11-28 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2008059043A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
WO2008059009A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
EP2081589B1 (en) * 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
CN101969984A (zh) * 2007-12-20 2011-02-09 昆士兰大学 调节止血的组合物及其用途
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN105126248B (zh) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
ITFI20110084A1 (it) 2011-04-22 2012-10-23 Kedrion Spa Nuovo processo per la preparazione di un concentrato di fv virus inattivato a partire da plasma umano, scalabile a livello industriale.
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2021113800A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
AU2021207815B2 (en) 2020-01-13 2026-03-26 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
KR20230107625A (ko) 2020-11-13 2023-07-17 알닐람 파마슈티칼스 인코포레이티드 응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins

Also Published As

Publication number Publication date
GR3036000T3 (en) 2001-09-28
DE69520569D1 (de) 2001-05-10
AU697205B2 (en) 1998-10-01
EP0756638A1 (en) 1997-02-05
JP3810080B2 (ja) 2006-08-16
JPH09512425A (ja) 1997-12-16
US6083905A (en) 2000-07-04
ATE200225T1 (de) 2001-04-15
CA2188463C (en) 2007-12-11
EP0756638B1 (en) 2001-04-04
AU2319495A (en) 1995-11-16
DK0756638T3 (da) 2001-07-23
CA2188463A1 (en) 1995-11-02
WO1995029259A1 (en) 1995-11-02
DE69520569T2 (de) 2001-10-04

Similar Documents

Publication Publication Date Title
ES2157326T3 (es) Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea.
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
CY1113145T1 (el) Μορια υποδοχεα θυμικης στρωματικης λεμφοποιητινης και χρησεις αυτων
NO20010446L (no) Substituert anilidforbindelser og metoder
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
DE69938183D1 (de) Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
PT1214600E (pt) Determinacao de proteinas de ligacao a adrenomedulina
SE8902532D0 (sv) Bestaemning av plasmaproteiner
Babinska et al. Two regions of the human platelet F11-receptor (F11R) are critical for platelet aggregation, potentiation and adhesion
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DE69033511D1 (de) Verfahren zum Nachweis von Knochen- und anderen Bindegewebeerkrankungen in Menschen und Tieren
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
Kimura et al. Twenty-seven base pair deletion in erythrocyte band 3 protein gene responsible for Southeast Asian ovalocytosis is not common among Southeast Asians
EP1233075A3 (en) BDNF polymorphism and association with bipolar disorder
DE20213920U1 (de) Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
NZ514691A (en) Method to type prion proteins
WO2003025197A3 (en) Mutant sh3-binding protein compositions and methods
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
DE69635989D1 (de) Diagnostischer test für von pferdearthritisvirus verursachte krankheiten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 756638

Country of ref document: ES